Boston Scientific Corporation is gaining traction as analysts affirm their confidence with a 'Buy' rating and a price target of $120, suggesting a potential 28% upside. The company anticipates a robust revenue increase to $5.27 billion, while making significant strides in pain and obesity treatment through acquisitions and new clinical studies. Despite a recent mixed performance and a year-over-year decline in shares, Boston Scientific's strategic growth initiatives position it favorably in the competitive medical device market.
“Boston Scientific Corporation · is one of the · 12 best Medical Devices stocks to invest in · according to Hedge Funds”
“Richard Newitter from Truist Securities · reiterated his · Buy rating on Boston Scientific Corporation · $120”
“Richard Newitter from Truist Securities · set a price target of · Boston Scientific Corporation · implying almost 28% upside”
“Morgan Stanley · reiterated its · positive view on Boston Scientific Corporation · following the Penumbra deal”
“Boston Scientific Corporation · specializes in · medical devices for interventional specialties · such as cardiovascular, endo-surgery, and neuro-modulation”
“Boston Scientific Corporation · offers a range of devices including · biliary stent systems, electrocautery enhanced delivery systems, direct visualization systems, and single-use duodeno-scopes”
“Boston Scientific · reported · third-quarter 2025 adjusted EPS of 75 cents · true”
“Boston Scientific · is · expanding its neuromodulation presence · through the acquisitions of Nalu Medical and Valencia Technologies”
“Boston Scientific · recently shared · new clinical data on spinal cord stimulation therapies · for pain management”
“Boston Scientific · launched · a clinical study · in Asia to evaluate the OverStitch NXT device for obesity treatment”
“Boston Scientific · is trading at · $92.33”
“Boston Scientific · shows · mixed recent performance · with a 1.1% gain over the past week and a 3.8% decline over the past month”
